📊 ABVC Key Takeaways
Is Abvc Biopharma, Inc.. (ABVC) a Good Investment?
ABVC faces an acute liquidity crisis with cash reserves of only $140K against annual operating cash burn of $894K, a current ratio of 0.12x indicating inability to cover near-term obligations, and a 41.9% revenue collapse that has rendered the company deeply unprofitable. The combination of negative operating cash flow, severe net losses, and minimal revenue generation creates existential solvency risk within months.
ABVC Biopharma’s fundamentals are very weak: revenue is declining, operating losses remain extreme relative to its revenue base, and the business is consuming cash with negative operating and free cash flow. While leverage is low and the balance sheet is not heavily debt-funded, the very weak liquidity position and continued cash burn make the growth profile low quality and increase financing risk.
Abvc Biopharma, Inc.. Key Strengths (ABVC)
- Minimal leverage with debt-to-equity ratio of 0.01x provides low bankruptcy protection but preserves capital structure
- Positive gross profit of $796K suggests some revenue contribution, though offset by operating expenses
- Stockholders equity of $10.8M provides technical asset cushion against liabilities
- Low debt burden with minimal long-term debt relative to equity
- Positive gross profit indicates some monetizable revenue sources or non-core income support
- Asset base and equity remain above total liabilities, providing some balance sheet cushion
ABVC Stock Risks: Abvc Biopharma, Inc.. Investment Risks
- Critical liquidity crisis: 0.12x current ratio with only $140.3K cash cannot sustain operations burning $894.2K annually, indicating runway of ~6 weeks
- Revenue collapse of 41.9% YoY signals fundamental business failure; $296K quarterly revenue insufficient to cover operating costs of $1.6M+
- Negative free cash flow of $915.4K with no visible path to profitability; unsustainable cash burn in unprofitable biotech/pharma sector
- Zero insider activity in 90 days suggests lack of confidence from management; no capital raises or strategic actions evident
- Current ratio of 0.41x and cash of only $681.48K indicate significant near-term liquidity pressure
- Revenue declined 41.9% YoY, pointing to weak commercial traction and poor growth quality
- Operating loss of $7.15M and free cash flow of -$3.01M show the business is far from self-funding
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway (critical threshold: <$100K cash)
- Revenue trend stabilization or further decline YoY
- Operating cash flow recovery to positive territory
- Debt covenant compliance and refinancing/capital raise announcements
- Cash runway including quarterly operating cash burn
- Revenue growth consistency and improvement in operating loss margin
Abvc Biopharma, Inc.. (ABVC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ABVC Profit Margin, ROE & Profitability Analysis
ABVC vs Healthcare Sector: How Abvc Biopharma, Inc.. Compares
How Abvc Biopharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Abvc Biopharma, Inc.. Stock Overvalued? ABVC Valuation Analysis 2026
Based on fundamental analysis, Abvc Biopharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Abvc Biopharma, Inc.. Balance Sheet: ABVC Debt, Cash & Liquidity
ABVC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Abvc Biopharma, Inc..'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-0.42 indicates the company is currently unprofitable.
ABVC Revenue Growth, EPS Growth & YoY Performance
ABVC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $200.0K | -$842.1K | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Abvc Biopharma, Inc.. Dividends, Buybacks & Capital Allocation
ABVC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Abvc Biopharma, Inc.. (CIK: 0001173313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABVC
What is the AI rating for ABVC?
Abvc Biopharma, Inc.. (ABVC) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABVC's key strengths?
Claude: Minimal leverage with debt-to-equity ratio of 0.01x provides low bankruptcy protection but preserves capital structure. Positive gross profit of $796K suggests some revenue contribution, though offset by operating expenses. ChatGPT: Low debt burden with minimal long-term debt relative to equity. Positive gross profit indicates some monetizable revenue sources or non-core income support.
What are the risks of investing in ABVC?
Claude: Critical liquidity crisis: 0.12x current ratio with only $140.3K cash cannot sustain operations burning $894.2K annually, indicating runway of ~6 weeks. Revenue collapse of 41.9% YoY signals fundamental business failure; $296K quarterly revenue insufficient to cover operating costs of $1.6M+. ChatGPT: Current ratio of 0.41x and cash of only $681.48K indicate significant near-term liquidity pressure. Revenue declined 41.9% YoY, pointing to weak commercial traction and poor growth quality.
What is ABVC's revenue and growth?
Abvc Biopharma, Inc.. reported revenue of $296.0K.
Does ABVC pay dividends?
Abvc Biopharma, Inc.. does not currently pay dividends.
Where can I find ABVC SEC filings?
Official SEC filings for Abvc Biopharma, Inc.. (CIK: 0001173313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABVC's EPS?
Abvc Biopharma, Inc.. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ABVC's fundamental grade?
Based on our AI fundamental analysis in June 2026, Abvc Biopharma, Inc.. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ABVC stock overvalued or undervalued?
Valuation metrics for ABVC: ROE of -14.5% (sector avg: 15%), net margin of -527.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ABVC's AI grade for 2026?
Our dual AI analysis gives Abvc Biopharma, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABVC's free cash flow?
Abvc Biopharma, Inc..'s operating cash flow is $-894.2K, with capital expenditures of $21.2K. FCF margin is -309.3%.
How does ABVC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -527.1% (avg: 12%), ROE -14.5% (avg: 15%), current ratio 0.12 (avg: 2).